1. Home
  2. TIL vs SRBK Comparison

TIL vs SRBK Comparison

Compare TIL & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TIL
  • SRBK
  • Stock Information
  • Founded
  • TIL 2018
  • SRBK 1887
  • Country
  • TIL United States
  • SRBK United States
  • Employees
  • TIL N/A
  • SRBK N/A
  • Industry
  • TIL Biotechnology: Pharmaceutical Preparations
  • SRBK
  • Sector
  • TIL Health Care
  • SRBK
  • Exchange
  • TIL Nasdaq
  • SRBK Nasdaq
  • Market Cap
  • TIL 230.1M
  • SRBK 117.4M
  • IPO Year
  • TIL 2021
  • SRBK N/A
  • Fundamental
  • Price
  • TIL $23.87
  • SRBK $14.52
  • Analyst Decision
  • TIL Buy
  • SRBK
  • Analyst Count
  • TIL 5
  • SRBK 0
  • Target Price
  • TIL $119.00
  • SRBK N/A
  • AVG Volume (30 Days)
  • TIL 310.5K
  • SRBK 116.7K
  • Earning Date
  • TIL 08-12-2025
  • SRBK 07-25-2025
  • Dividend Yield
  • TIL N/A
  • SRBK 1.37%
  • EPS Growth
  • TIL N/A
  • SRBK N/A
  • EPS
  • TIL N/A
  • SRBK N/A
  • Revenue
  • TIL N/A
  • SRBK $27,988,000.00
  • Revenue This Year
  • TIL N/A
  • SRBK N/A
  • Revenue Next Year
  • TIL N/A
  • SRBK N/A
  • P/E Ratio
  • TIL N/A
  • SRBK N/A
  • Revenue Growth
  • TIL N/A
  • SRBK 23.80
  • 52 Week Low
  • TIL $9.85
  • SRBK $9.33
  • 52 Week High
  • TIL $92.00
  • SRBK $14.96
  • Technical
  • Relative Strength Index (RSI)
  • TIL 46.54
  • SRBK 81.41
  • Support Level
  • TIL $23.38
  • SRBK $14.28
  • Resistance Level
  • TIL $26.91
  • SRBK $14.96
  • Average True Range (ATR)
  • TIL 3.25
  • SRBK 0.25
  • MACD
  • TIL -0.32
  • SRBK 0.13
  • Stochastic Oscillator
  • TIL 31.75
  • SRBK 85.46

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About SRBK SR Bancorp Inc. Common stock

SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.

Share on Social Networks: